On a GLP-1 medication with reduced food intake, this fear becomes counterproductive
Instead, they often peaked during titration and then levelled off, meaning that once participants were settled into their maintenance schedule, side effects tended to diminish rather than worsen
Theres no medical requirement to increase on exactly a four-week schedule
GLP-1 Game-Changer: How Oral GLP-1s Will Shape Health Plan Strategy Authored by Leslie Lotano-Saba GLP-1s for diabetes and obesity are already a top concern of health plan CEOs, with the category forecasted to achieve 13% to 15% CAGR growth from 2024 to 2034, reaching approximately $130 billion in total market size
Weight loss is tough, and no one should have to go through it alone
A triumph The new generation of appetite-suppressing drugs using GLP-1 agonists -- which include the brands Ozempic, Wegovy and Mounjaro -- have exploded in popularity in recent years due to their ability to help people lose weight
